Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Stock Information for Qualigen Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Qualigen Therapeutics Inc.

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.